Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Gazzah, A. [1 ]
Lee, J. S. [2 ]
Wang, E. [2 ]
Ternes, N. [3 ]
Wang, H. [2 ]
Boitier, E. [3 ]
Lartigau, A. [3 ]
Chadjaa, M. [3 ]
Dib, C. [3 ]
Muzard, G. [3 ]
Valence, S. [3 ]
Remaury, A. [3 ]
Palu, C. C. [4 ]
Bauchet, A-L. [3 ]
机构：
[1] Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Sanofi, Cambridge, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
71P
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [31] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Rodon, Jordi
    Jacobs, Charlotte D.
    Chu, Quincy
    Rowinsky, Eric K.
    Lopez-Anaya, Arturo
    Takimoto, Chris H.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 825 - 834
  • [32] Phase II study of Gemcitabine, ifosfamide and cisplatin (GIP) in patients with advanced non-small cell lung cancer (NSCLC)
    De las Penas, R
    Busquier, I
    Munarriz, J
    Lopez, A
    Llorente, R
    Alberola, V
    Frau, A
    ANNALS OF ONCOLOGY, 1998, 9 : 88 - 88
  • [33] Gemcitabine combined with cisplatin in non-small cell lung cancer (NSCLC): A phase I/II study
    Steward, WP
    Dunlop, DJ
    Cameron, C
    Talbot, DC
    Kleisbauer, JL
    Thomas, P
    Guerin, JC
    Perol, M
    Sanson, C
    Dabouis, G
    Lacroix, H
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1081 - 1081
  • [34] Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy.
    Johnson, Melissa Lynne
    Chadjaa, Mustapha
    Yoruk, Semra
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer
    Hotta, K
    Sekine, I
    Tamura, T
    Sawada, M
    Watanabe, H
    Kusaba, H
    Akiyama, Y
    Inoue, A
    Shimoyama, T
    Nokihara, H
    Ueda, Y
    Yamamoto, N
    Kunitoh, H
    Ohe, Y
    Kodama, T
    Saijo, N
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (12) : 596 - 600
  • [36] Carboplatin and vinorelbine in advanced non-small cell lung cancer: A phase I/II study
    Masters, G
    ONCOLOGIST, 2001, 6 : 12 - 15
  • [37] Phase I/II study of weekly docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
    Hirata, T
    Kawashita, F
    Ogawa, E
    Masago, K
    Kato, M
    Takada, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 676S - 676S
  • [38] Evaluation of combined biomarker in response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC)
    Ramdani, H. O.
    Shatz, S.
    Falk, M.
    Heukamp, L. C.
    Tiemann, M.
    Wesseler, C.
    Schuuring, E.
    Groen, H. J.
    Griesinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 153 - 153
  • [39] PHASE I/II STUDY OF S-1 PLUS CARBOPLATIN (CBDCA) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Tamura, K.
    Okamoto, I.
    Ozaki, T.
    Kashii, T.
    Takeda, K.
    Kobayashi, M.
    Matsui, K.
    Shibata, T.
    Nakagawa, K.
    Fukuoka, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 108 - 108
  • [40] Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC):: a phase I trial
    Krajnik, G
    Wein, W
    Greil, R
    Marhold, F
    Mohn-Staudner, A
    Kummer, F
    Malayeri, R
    Zöchbauer-Müller, S
    Huber, H
    Pirker, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1977 - 1980
12345